Concept Of Digital Disruption Within Bayer
Task Summary: This assessment task requires you to research and write a 1000 words report on the topic related to the key information systems concepts and technologies evident in the context of contemporary businesses and organisations.
Context: The purpose of this assignment is to develop your ability to understand the use of information systems technologies and concepts such as innovation, digital disruption, cultural impact and new business models in the contemporary workplace.
Digital Disruption is the transition that arises as new advanced technologies and action plans impact the production capacity of existing products and initiatives (McLoughlin, Garrety & Wilson, 2017). The organizations based on different sectors must accept this digital disruption to have a comparative advantage in its production procedure. This therefore gives companies a comprehensive understanding of human behaviour and how trends can occur during that time (Skog, Wimelius & Sandberg, 2018). The digital disruption is widely accepted by the medical and healthcare industries like Bayer. Bayer is a well-established global company having a large-scale impact on the healthcare and pharmaceutical industry. The current presentation discusses the concept of digital disruption in the context of medical and healthcare industries using the example of the global company- Bayer ("Bayer – Global Home", 2020).
Gabor George Burt, the founder of the Slingshot Group, stated that significant advancement shouldn't be founded on the whole innovation. There is always an invigorating alternate route. It depends on a strong, new blend of previously existing constituents that at the same time open the increased degrees of customer esteem and reduce costs.
Digital Disruption in the medical and health industries:
This statement of Gabor George Brut is true in every sense in the context of the medical and health industries. Considering the case of a global pharmaceutical company Bayer, it is seen that the company has been using digital disruption to improve the medical and healthcare system.
Bayer has developed new strategies and a strong digital team to maintain the effects of digital disruption in Bayer. Bayer has started using Artificial Intelligence technologies to develop new pharmaceutical products utilizing new digital technologies with a lower cost of production. Brilliant innovations like AI are considered as aspects of the digital disruption in the company like Bayer (Ford, Compton, Millett & Tzortzis, 2017). In these kinds of situations, Bayer's goal is to encourage the pharmacy executives to release dreary responsibilities to communicate with relevant data and settle on choices based on past insights obtained. In this, increased automation will encourage flexible employees to build different activities where more of it is expected. Setting aside both time and cash, Bayer is now also defending the new businesses related to digital health with its Grants4Apps Accelerator coaching program. A year ago, the principal clump of five new companies was picked to move into Bayer's Berlin grounds from August to December. The initiation of the Internet of Medical things makes Bayer more prosperous. The medication revelation specialists of Bayer essentially focus on the zones of cardiovascular problems, oncology and gynaecological treatments. They have been searching for either little particles or biologics that could fill in as new dynamic fixings. Bayer keeps on creating items even after they have been endorsed to advance patient advantage through new conveyance structures or a more extensive scope of signs (Krämer and Kalka, 2017).
Achieving higher levels of patient care quality using disruptive technologies
Supplementing exploration limits are joint efforts and vital coalitions with outside accomplices in the scholarly world and industry. Bayer is persuaded about the fact that the solid organizations animate advancement and encourage the joint improvement of new methodologies that finally causes an advantage to the patients which help the patients to get better healthcare facilities at a lower price because of the usage of disruptive technologies. The company like Bayer has its research centres for R&D (Vesti, Rosenstand & Gertsen, 2018). America and Asia also have their centre points in the United States, San Francisco and similar other places. Bayer has also taken large scale initiatives regarding programmes like Open Innovation which facilitates the patients through the availability of better medical facilities. The research and development process gets a large amount of investment in the concerned company which ensures the availability of cheaper medicines and other related products which ultimately benefits the patient party (Sullivan and Staib, 2018). Bayer has also claimed that it is likewise available to profoundly creative digital wellbeing programming to give the patients more satisfactory services. The innovative technologies related to Digital health support the pharmaceutical organizations to assemble their esteem story for the items which are produced or invented in recent days. Some organizations which are little in size may even create approaches to include a serious digital health advancement to offer the medication at its modest price. This in turn helps the patient party to have a better treatment at a lesser price (Herrmann et al., 2018).
But this Digital Disruption sometimes disrupts the health and medicine industry as some forces are working against the positive flow of this innovation. In some cases, the quality of services provided through this is below the average standard (Laurenza, Quintano, Schiavone & Vrontis, 2018). The patient party sometimes is considered to be not eligible for this lower-cost service at all. The accessibility of low-cost medicines is not always seen in every case. However, the underdeveloped economy suffers mostly in such disruption cases. But above all, such an innovative innovation must be highly supported especially by the government of the concerned country so that it can reach all the people irrespective of their background around the world (Bauer, Hodsdon, Bechtel, & Fortney, 2018).
All over the globe, Digital Disruption is seen to happen with the advancements, telemedicine, and administrations of health sectors, having suppliers, wellbeing plans, and pharma organizations are developing the new models to bring the administrations into focus as opposed to simply advancing the item. In this presentation it is shown that, the process of digitalisation in the company Bayer, helps in the improvement of the overall health industry from both the consumer and producer approaches. The digital disruption benefits the patients as well as Bayer through better healthcare facilities at a lower cost. Bayer is seen to invest in Research and Development through collaboration with other companies which in turn help in the advancement of the medical system as a whole. From the business point of view of Bayer, the profitability conditions have been fulfilled which in turn has provided incentives to the company like Bayer to invest more in R&D. Lastly, it can be said that the statement of Gabor George Burt is true in every sense as the presence of digital disruption has changed the viewpoint of the whole Medical and Health Care systems as well as the other sectors.
Bauer, A. M., Hodsdon, S., Bechtel, J. M., & Fortney, J. C. (2018). Applying the principles for digital development: a case study of a smartphone app to support collaborative care for rural patients with posttraumatic stress disorder or bipolar disorder. Journal of medical Internet research, 20(6), e10048.
Ford, G., Compton, M., Millett, G., & Tzortzis, A. (2017). The role of digital disruption in healthcare service innovation. In-Service business model innovation in healthcare and hospital management (pp. 57-70). Springer, Cham.
Herrmann, M., Boehme, P., Mondritzki, T., Ehlers, J. P., Kavadias, S., & Truebel, H. (2018). Digital transformation and disruption of the health care sector: an internet-based observational study. Journal of medical internet research, 20(3), e104.
Krämer, A., & Kalka, R. (2017). How digital disruption changes pricing strategies and price models. In Phantom Ex Machina (pp. 87-103). Springer, Cham.
Laurenza, E., Quintano, M., Schiavone, F., & Vrontis, D. (2018). The effect of digital technologies adoption in the healthcare industry: a case-based analysis. Business process management journal.
McLoughlin, I. P., Garrety, K., & Wilson, R. (2017). The digitalization of healthcare: Electronic records and the disruption of moral orders. Oxford University Press.
Skog, D. A., Wimelius, H., & Sandberg, J. (2018). Digital disruption. Business & Information Systems Engineering, 60(5), 431-437.
Sullivan, C., & Staib, A. (2018). Digital disruption ‘syndromes’ in a hospital: important considerations for the quality and safety of patient care during rapid digital transformation. Australian health review, 42(3), 294-298.
Vesti, H., Rosenstand, C. A. F., & Gertsen, F. (2018). Structured Literature Review of digital disruption literature. In ISPIM Conference Proceedings (pp. 1-12). The International Society for Professional Innovation Management (ISPIM).
Bayer – Global Home. (2020). Retrieved 7 October 2020, from https://www.bayer.com/en/